The NCCN’s updated guidelines for the treatment of breast cancer include updates on sentinel lymph node biopsy, ovarian function suppression, and the use of prognostic tools.

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance and Faslodex.

In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and ...

The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

Cancer treatment is so much more exciting now than it was even 5 or 10 years ago, because not only are treatments so much better, but they're so much easier to take. The stage of cancer is one of the ...

After you’re diagnosed with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer, your doctor’s goal is to build a treatment plan that gives you the best chance of controlling your ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy. The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab ...

“Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...